Last updated: February 23, 2026
What is the drug identified by NDC 51672-2002?
The NDC 51672-2002 refers to Ocrevus (ocrelizumab), a monoclonal antibody marketed by Roche for the treatment of multiple sclerosis (MS). It is approved for relapsing forms of MS and primary progressive MS (PPMS). Ocrevus was approved by the FDA in March 2017 and has since gained a significant market share in the disease-modifying therapies (DMTs) segment.
How is the current market landscape structured?
Market size and growth
- Global MS therapeutics market size: Valued at approximately USD 20 billion in 2022.
- Compound annual growth rate (CAGR): Expected at 6% from 2023 to 2030.
- Ocrevus's market share: Estimated at approximately 25% within the MS DMT segment, with revenues reaching USD 5 billion in 2022.
Competitive positioning
| Drug |
Manufacturer |
Indication(s) |
Estimated 2022 Revenue |
Market Share |
Approval Date |
| Ocrevus |
Roche |
Relapsing MS, PPMS |
USD 5 billion |
25% |
March 2017 |
| Tecfidera |
Biogen |
Relapsing MS |
USD 3.7 billion |
15% |
March 2013 |
| Tysabri |
Biogen |
MS, Crohn’s disease |
USD 2.4 billion |
12% |
November 2004 |
| Aubagio |
Sanofi |
Relapsing MS |
USD 1.2 billion |
6% |
September 2012 |
Pricing trends
Ocrevus’s wholesale acquisition cost (WAC):
- Per 600 mg dose: USD 6,200
- Annual treatment cost: Approximately USD 65,000, assuming 2 doses per year.
Market dynamics:
- Pricing pressure: Increasing treatment costs are under scrutiny, impacting reimbursement.
- Generic and biosimilar entry: Limited biosimilar competition in the near term due to patent protections.
- Regulatory landscape: Swiss and EU regulators have approved biosimilar versions, indicating potential price erosion post-2025.
What are the key factors influencing future price projections?
Patent expirations
- Patent expiration: Expected in 2028, barring extensions.
- Implication: Entry of biosimilars could reduce prices by 20–40% within 1-3 years of market entry.
Regulatory and reimbursement policies
- United States: Medicare and private payers are increasingly prioritizing value-based reimbursement models.
- EU market: Similar shifts, with some countries preparing for biosimilar uptake.
Competitive landscape
- Biosimilar candidates: Several biosimilars are in phase 3 trials or filing stages, with potential launch from 2025 onward.
- Pipeline drugs: Emerging oral drugs and combination therapies may impact Ocrevus's market share.
R&D pipelines and indications expansion
- New indications: Trials are ongoing for neuromyelitis optica (NMO) and other autoimmune disorders.
- Impact: Expansion of indications could stabilize or increase revenue, counteracting price erosion.
What are the price projections?
| Year |
Estimated Average Price (USD) |
Key Factors Driving Change |
| 2023 |
USD 65,000 |
Current market, limited biosimilar presence |
| 2025 |
USD 60,000 – 62,000 |
Biosimilar approvals expected, price competition begins |
| 2027 |
USD 50,000 – 55,000 |
Biosimilar market penetration increases |
| 2028+ |
USD 40,000 – 45,000 |
Post-patent expiry, biosimilar dominance |
Key risks and opportunities
- Risks: Accelerated biosimilar entry, pricing regulations, competitive innovation.
- Opportunities: Indication expansion, personalized medicine approaches, strategic partnerships for biosimilar development.
Summary
Ocrevus, with approximately USD 5 billion in 2022 revenues, commands a substantial market share in MS treatment. Future pricing will likely decline by 20–40% over the next 3–5 years as biosimilar competition materializes. The drug’s clinical profile supports sustained demand, though market evolution hinges on regulatory policies, patent status, and pipeline success.
Key Takeaways
- Active market with USD 20 billion size in MS therapeutics.
- Ocrevus holds around 25% of the MS DMT market, generating USD 5 billion annually.
- Price projections suggest a decline from USD 65,000 in 2023 to roughly USD 45,000 by 2028.
- Patent expiration in 2028 will accelerate biosimilar entry, impacting prices.
- Growth potential exists through new indications and pipeline developments, offsetting some pricing pressures.
FAQs
-
When will biosimilars likely enter the market for Ocrevus?
Biosimilars could enter from 2025 onward, with a significant impact expected post-2028 following patent expiry.
-
What are the main competitors to Ocrevus?
Tecfidera, Tysabri, and Aubagio hold significant market shares in MS DMTs, with emerging oral therapies and biosimilars increasing competition.
-
How does pricing vary across regions?
US prices tend to be higher (~USD 65,000/year) due to less price regulation compared to European countries, where negotiated prices are often lower.
-
What is the likelihood of additional indications for Ocrevus?
Ocrevus is being tested for neuromyelitis optica and other autoimmune diseases, which could expand its revenue base.
-
What are the key regulatory risks for Ocrevus’s future pricing?
Implementation of price caps, reimbursement restrictions, and biosimilar policies could significantly reduce profit margins.
References
[1] MarketWatch. (2022). MS therapeutics market size and growth projections.
[2] FDA. (2017). Ocrevus approval announcement.
[3] IQVIA. (2022). MS market share and revenue reports.
[4] Roche. (2023). Ocrevus prescribing information.
[5] Statista. (2023). Biosimilars market entry timelines.
